Results 1 to 10 of about 2,114,452 (380)

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

npj Vaccines, 2021
RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immune correlates of protection (CoP) are elusive. To identify
Kelly E. Seaton, Rachel L. Spreng, Milite Abraha, Matthew Reichartz, Michelle Rojas, Frederick Feely, Richard H. C. Huntwork, Sheetij Dutta, Sarah V. Mudrak, S. Munir Alam, Scott Gregory, Erik Jongert, Margherita Coccia, Fernando Ulloa-Montoya, Ulrike Wille-Reece, Georgia D. Tomaras, S. Moses Dennison   +16 more
doaj   +1 more source

Psoriasis: To Vaccinate or Not to Vaccinate? [PDF]

Cureus, 2021
Psoriasis is a chronic, inflammatory, autoimmune disease characterized by red, dry, itchy, and scaly patches of abnormal skin growth on the elbows, knees, and/or scalp, which can negatively impact a patient's quality of life and activities of daily living.
Marc M Kesselman, Michelle Demory Beckler, Poonam Patel, Christian Summa   +3 more
openaire   +3 more sources

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

npj Vaccines, 2022
Vaccination with typhoid conjugate vaccines (TCV) is a major part of typhoid prevention. However, little is known about long-term immune persistence following vaccination with TCVs.
Maria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, Edison Alberto, Deok Ryun Kim, Eun Lyeong Park, Ju Yeon Park, Jae Seung Yang, Jagadeesh Reddy Eluru, Sue-Kyoung Jo, Hun Kim, Seon-Young Yang, Ji Hwa Ryu, Hokeun Park, Jong Hoon Shin, Yoonyeong Lee, Jerome H. Kim, Zenaida Reynoso Mojares, T. Anh Wartel, Sushant Sahastrabuddhe   +19 more
doaj   +1 more source

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches

Human Vaccines & Immunotherapeutics, 2022
Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after ...
Judith Absalon, Raphael Simon, David Radley, Peter C. Giardina, Kenneth Koury, Kathrin U. Jansen, Annaliesa S. Anderson   +6 more
doaj   +1 more source

Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. [PDF]

, 2013
BackgroundLittle is known on the effectiveness of influenza vaccine in ESRD patients. This study compared the incidence of hospitalization, morbidity, and mortality in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) between cohorts ...
Chang, Chiz-Tzung, Huang, Chiu-Ching, Liang, Chih-Chia, Lin, Cheng-Li, Lin, Po-Chang, Liu, Yao-Lung, Morisky, Donald E, Sung, Fung-Chang, Wang, I-Kuan, Yen, Tzung-Hai   +9 more
core   +6 more sources

VACCINATION. [PDF]

The Lancet
n ...
  +22 more sources

Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems [PDF]

, 2014
Cervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors.
Atyabi, F., Ghaemi, A., Gorji, A., Kalhor, H.R., Kelishadi, M., Moradi, A., Sajadian, A., Tabarraei, A., Tahamtan, A.   +8 more
core   +8 more sources

Vaccine Innovation Conference 2017

Journal of Pharmacy & Pharmaceutical Sciences, 2017
Proceedings from the Vaccine Innovation Conference 2017, held May 10, 2017, at Hyatt Regency Hotel, Montréal, QC, Canada, Presented by: Vaccine Industry ...
Vaccine Industry Committee
doaj   +1 more source

Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves [PDF]

, 2015
peer-reviewedBackground There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by
A Menanteau-Horta, A Vila, AR Peters, B Morein, B Morein, Bernadette Earley, BJF Bradshaw, BM Adair, Bryan Markey, C Pilette, CA Siegrist, CX Song, DG Bryson, DP Greenberg, EM Liebler-Tenorio, F Alexis, F Mansoor, Fawad Mansoor, FM Buonaguro, HM Chen, I Vangeel, J Phillips, J Pollock, JE Crowe, Joseph P. Cassidy, JS Salt, K Tahara, KJ Wiechelman, M Garinot, M Higaki, Michael D. Welsh, ML Hans, MS Lee, OV Kavanagh, PE Shewen, PK Smith, PR Wood, RE Brown, RM Zinkernagel, S Lofthouse, Simon Doherty, TG Kimman, YJ Kwon   +42 more
core   +1 more source

Global economic burden per episode for multiple diseases caused by group A Streptococcus

npj Vaccines, 2023
Considering the lack of existing evidence on economic burden for diseases caused by group A Streptococcus, we estimated the economic burden per episode for selected diseases.
Jung-Seok Lee, Sol Kim, Jean-Louis Excler, Jerome H. Kim, Vittal Mogasale   +4 more
doaj   +1 more source